DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Aducanumab is an investigational drug.
There have been 8 clinical trials for Aducanumab. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2015.
The most common disease conditions in clinical trials are Alzheimer Disease, Dementia, and Cognitive Dysfunction. The leading clinical trial sponsors are Biogen and [disabled in preview].
There are six US patents protecting this investigational drug and forty-one international patents.
Recent Clinical Trials for Aducanumab
|A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205||Biogen||Phase 3|
|A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalit||Biogen||Phase 2|
|Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants||Biogen||Phase 1|
Top disease conditions for Aducanumab
Top clinical trial sponsors for Aducanumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Aducanumab||Get Started Free||Intranasal administration of guanidinylated aminoglycosides||THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)||Get Started Free|
|Aducanumab||Get Started Free||Binding-triggered transcriptional switches and methods of use thereof||The Regents of the University of California (Oakland, CA)||Get Started Free|
|Aducanumab||Get Started Free||Cell culture medium||LA JOLLA BIOLOGICS, INC. (San Diego, CA)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Aducanumab||World Intellectual Property Organization (WIPO)||WO2014159878||2033-03-13||Get Started Free|
|Aducanumab||Australia||AU2015348012||2034-11-19||Get Started Free|
|Aducanumab||Australia||AU2020227007||2034-11-19||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|